We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
At current prices they will be getting about £600k a year from that agreement… they burn £3.5m a year so they will be running on fumes atm. A placing will imo be required in the next few weeks, we just have to hope it’s not at a big discount, I’d be happy with a 5.5p placing tbh as that’s been the average price over the last month or so and only a 10% discount, I just hope they don’t screw us as the nominal value was changed to 1p
Actually.. looks like the £1.6m there end of December included the £3.5m raise, with something like £2.4m deferred as part of sharing agreement. So - depends how much they get from sharing agreement I guess.
Why do a placing now, if they are confident of good news? Unless they aren’t confident of good news. Cash balance end December was around £5m, including the December cash raise, easily enough to see them through this year. They will also be getting something in from Lanstead.
It will definitely be below 11p Dallo don’t kid yourself on that, that was the reason for changing the nominal value from 10p to 1p so they could do a placing at less than 10p and upwards of 1p, Avion should back it again I just hope Tim doesn’t use the excuse that the market for funding is terrible atm and offer a huge discounted placing for mates rates etc, if it’s discounted to 5p for Avion alone then I could stomach that, just not a 30% discounted placing as we have seen in the past in 2020
Lambo
I don't think they do a placing at less than 11p particularly as we are on the cusp of significant and transformational news.
Don't rule out Avion taking another dollop at c 11p
Imho
They will probably do a placing in the next week or so imo, I have requested that shareholders are able to participate in any placing so hopefully this is offered and they don’t do a mates rate placing at a ridiculous discount… the market knows IMM need cash and it’s time for the BOD to take a good lump and be aligned with shareholders, fingers crossed they don’t screw us with a 5p placing
Nolupus
Fully agree but the approval by the FDA will change the investment case and set a floor ( hopefully mid teens) for the duration of the trial.
Also it could accelerate the discussions with potential rest of world partners for Lupuzor which could push the SP higher again if successful.
All to play but fingers firmly crossed as usual in IMMU.
ATB
Dallo,
I do agree that they are learning from past mistakes and therefore chances are higher of getting a positive result .
That said , we will have to wait and see the revised protocol and then review things .
Cautious optimism is the form :-)
Nolupus
There were always going to concentrate the new Phase 3 trial on the anti-ds DNA antibody positive cohort which showed very good results in the 1st Phase 3 ..Lupus sufferers with this biomark represent
around 60% of total.
With the enhanced P140 Lupuzor formulation the chances of a successful trial result in the biomark positive cohort which will comprise 100% of the test population, are excellent imho.
We now await the FDA for a possible groundbreaking decision for the investors in IMMU.
ATB
By my calculations they have enough cash to last until about the end of this month imo, I’m hopeful they can get a placing away at around 6p… last thing we need is a heavily discounted placing when news is only a couple of months away
Jonah58,
I also noticed that information which we were expecting but like you , I am awaiting the details for this ´ new and optimized P3 ‘
What this news confirms is that Avion are going after a certain population of lupus patients ( estimated 60% of sufferers) ….
One thing I picked up from the RNS is this:
"The new international Phase 3 clinical trial protocol requires the presence of the biomarker before being allowed into the study. This protocol was accepted by the FDA at the previous Type C meeting in 2021."
It seems to imply that the protocol for the forthcoming phase 3 trial is already written. This will include all sorts of crucial information such as criteria for admitting patients and the end points which I am very keen to know. The trial does not appear in the list I usually turn to:
https://clinicaltrials.gov/ct2/results?cond=Lupus+Erythematosus&Search=Apply&recrs=b&age_v=&gndr=&type=&rslt=
Does anyone have any further information about the protocol? Nolupus?
When you schedule a meeting you arrange a meeting…it’s arranged for 29th August so expect the feedback and minutes in early September, switch off time now over the summer months and come back in September when hopefully we will get some positive news. Still think we will need a keep the lights on placing between now and then but it should only be a small amount required, see you all in September and enjoy the summer
I think your exact wording was "FDA have 75 days to schedule a meeting but we cannot change how slowly the FDA work". I read that as 75 days to schedule a meeting, not for the meeting to be held and outcome known. Will have to see what the feedback is post the 29th Aug, however it does seem to me that the fact that this is being done in correspondence suggests some positivity.
News won’t be until September flipper so I was right! Meeting is on 29 August so news of the meeting won’t be out until September, a couple of months to wait so hopefully no placing in the meantime , as I said it’s switch off u til September now
Great news and pretty positive wording.
Admission of new ordinary shares of £0.01 following share capital reorganisation, was expected to be around Monday 4 July 2022. Market seems to be awaiting to see impact to begin accumulation pre-FDA meeting update.
Hopefully the delay means other news is upcoming
Let’s hope they don’t do a placing atm as the market is shocking, 30-40% discounted placings a regular occurrence on aim, I think Tim should dig deep and really back IMM in the next placing, it would definitely align him with shareholders and focus his mind, atm he gets paid regardless of performance which in any business is never good
Hi Dallo,
I’m also a long term holder, being here topping up for the last four years or so, I trust Immupharma but mainly Avion’s due diligence, investment, vision, recent announcement and efforts put on lupuzor. Yes, the value of our holdings should not be affected as I was informed by Lisa from Immupharma yesterday, just the nominal value for compliance purposes. The current volatility has not helped in the last couple of days but I really hope to see that changing soon…patience. All the best!
Oscar
It has been a long wait ..8 years in my case but stubbornly I kept holding .
Hopefully we will get our reward.
By the way the "new"shares to be listed replace exactly the current shares in issue ...the only change is the nominal value to accord with Companies Act...ie share price of issued shares cannot be below authorised nominal price....purely a regulatory adjustment and will not influence SP on Monday imho.
Hi Dallo,
The day of the meeting with the FDA should be announced shortly so hopefully this is not that far away and that helps the SP to start recovering. I have a similar holding than yours so I perfectly understand you but hopefully we can start seeing some light at the end of the tunnel soon!
@Drew57, my understanding is that the submission of the PK Study must be at least one month prior to the formal Type C meeting. After then, in theory the Type C meeting can be held at anytime but will have to be scheduled within 75 days of receiving the written meeting request, which is the September date. So for me that was the significance of the RNS. It looks like despite the slip back there has been no major worries of the admission of the new shares on the 04th July. The margin requirements are still quite here, which suggests some more news is expected before September, but let's see. TM continues to disappoint, sadly.
Big unwind by short term traders following Monday's
RNS when SP hit 7p briefly.
The realisation that we have another 2 months to wait before the fateful and pivotal FDA Phase 3 decision has driven the short-termers to the sidelines but they will be back in a couple of weeks.
Hang in there and ATB
The 27th June RNS states " Avion has submitted, via a Type C Meeting, the positive results from the Lupuzor™/P140 Pharmacokinetic ("PK") study to the FDA."
Why does it say 'has submitted' in the past tense. Has the meeting already taken place? Am I missing something?